<p>➀ Trogenix, an Edinburgh-based biotech company, raised $95 million in Series A funding to advance precision cancer therapies targeting aggressive tumors like glioblastoma and colorectal liver metastases;</p><p>➁ The funds will support clinical trials for glioblastoma starting in 2026 and expand its pipeline for liver and lung cancers using the proprietary Odysseus platform;</p><p>➂ The technology combines cancer cell-killing and immune stimulation through Synthetic Super Enhancers (SSEs), offering long-term protection against tumor recurrence without harming healthy tissue.</p>